Dianthus Therapeutics (DNTH) Cash & Current Investments (2017 - 2025)

Dianthus Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $404.3 million for Q4 2025.

• In Q4 2025, Cash & Current Investments rose 46.89% year-over-year to $404.3 million; the TTM figure through Dec 2025 stood at $404.3 million (up 46.89% YoY), while the FY2025 annual figure was $404.3 million, up 46.89% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $404.3 million, roughly flat from $402.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $404.3 million in Q4 2025, with the low at $52.9 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $191.2 million (2021), against an average of $214.0 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments slumped 66.22% in 2023, then surged 612.8% in 2024.
• Dianthus Therapeutics' Cash & Current Investments stood at $176.9 million in 2021, then tumbled by 57.33% to $75.5 million in 2022, then jumped by 130.12% to $173.7 million in 2023, then soared by 58.44% to $275.2 million in 2024, then soared by 46.89% to $404.3 million in 2025.
• Business Quant data shows DNTH's Cash & Current Investments at $404.3 million in Q4 2025, $402.6 million in Q3 2025, and $257.4 million in Q2 2025.